Abstract

Twist Bioscience Corp will report fiscal third-quarter 2026 results on August 3, 2026 Pre-Market, with investors watching for delivery against its 114.00–115.00 million US dollars revenue guide, gross-margin stability near the low-50% range, and a year-over-year narrowing of adjusted EPS loss.

Market Forecast

For fiscal Q3 2026, Twist Bioscience Corp’s latest guidance and market tracking indicate revenue of approximately 114.49 million US dollars, a 19.73% year-over-year increase, and an adjusted EPS estimate of -0.494, implying an 11.63% year-over-year improvement in loss per share; EBIT is projected at -32.15 million US dollars, signaling a 7.52% year-over-year improvement. With no formal gross margin or net margin forecast disclosed for the quarter, investors are benchmarking expectations against last quarter’s 51.59% gross margin and monitoring whether operating expense discipline continues to narrow losses.

Management’s main-business outlook is concentrated on sustaining momentum across core customer groups that drove recent gains, while preserving pricing and improving utilization to keep gross margin around recent levels and improve operating leverage. The Therapeutics customer segment remains a central growth vector, contributing 40.77 million US dollars last quarter, with companywide fiscal Q3 guidance indicating continued double-digit year-over-year expansion and a constructive demand backdrop for this cohort.

Last Quarter Review

Twist Bioscience Corp delivered fiscal Q2 2026 revenue of 110.72 million US dollars, a gross margin of 51.59%, a GAAP net loss attributable to shareholders of 44.02 million US dollars with a net profit margin of -39.76%, and adjusted EPS of -0.59, representing a 10.61% year-over-year improvement in loss per share. A key highlight was the top-line outperformance versus the then-prevailing consensus by 3.06 million US dollars alongside a 19.31% year-over-year revenue increase, even as adjusted EPS came in below projections. By business mix, Therapeutics contributed 40.77 million US dollars and Diagnostics 39.96 million US dollars, together accounting for the bulk of revenue, with Academic Research & Government at 12.82 million US dollars, Global Supply Partners at 11.38 million US dollars, and Industrial and Applications at 5.80 million US dollars, supporting the company’s 19.31% year-over-year growth pace in the period.

Current Quarter Outlook (with major analytical insights)

Core revenue engine in fiscal Q3 2026

Twist Bioscience Corp guided fiscal third-quarter revenue to approximately 114.49 million US dollars, which implies a 19.73% year-over-year increase and builds on the 19.31% growth achieved in fiscal Q2. The updated revenue range of 114.00–115.00 million US dollars sets a clear bar, and execution will likely hinge on order conversion within the largest customer groups, shipment cadence late in the quarter, and fulfillment efficiency. Given last quarter’s 51.59% gross margin, the near-term focal point is whether the company can keep the gross margin band around the low-50% level while absorbing mix shifts between larger pharmaceutical and diagnostics customers and smaller accounts.

EBIT is estimated at -32.15 million US dollars for fiscal Q3, a 7.52% year-over-year improvement, aligning with the broader narrative of narrowing losses as revenue scales. This trend is echoed in the adjusted EPS estimate of -0.494, which implies an 11.63% year-over-year improvement and, if delivered, reinforces a path toward improved operating leverage over the next several quarters. Investors will also be attentive to any update on full-year revenue guidance after the recent increase into the 435.00–440.00 million US dollars range, since a reiteration or raise could recalibrate expectations for operating costs and cash use in the second half of fiscal 2026.

The operating expense trajectory is another swing factor. In the prior quarter, revenue growth outpaced EPS progress, suggesting continued investment alongside growth, but guidance now implies incremental efficiency. If Twist Bioscience Corp delivers on the revenue plan while holding gross margin near recent levels, the incremental expansion in gross profit dollars would help compress operating losses. Against that context, even modest upside to the revenue midpoint could have an outsized impact on the magnitude of EPS improvement, particularly if fixed costs remain in check.

Highest-potential business: Therapeutics customers

Within the company’s revenue mix, Therapeutics customers contributed 40.77 million US dollars last quarter, edging out Diagnostics as the largest contributor. The company’s fiscal Q3 guide implies healthy overall demand, and the Therapeutics cohort tends to be associated with larger and repeat orders driven by ongoing programs across drug discovery and development workflows. Sustained strength in this segment would underpin both the top line and mix quality, which can matter for gross margin if higher-value orders carry better absorption dynamics.

While segment-level year-over-year growth figures were not disclosed, the company’s projected 19.73% year-over-year revenue increase for fiscal Q3 suggests that the largest customer groups are expected to continue expanding. If Therapeutics retains or extends its share within the mix, that could translate into steadier quarterly revenue cadence and reduce volatility, a consideration that often weighs on valuation for companies driving toward profitability. Furthermore, predictable demand from larger customers can facilitate production planning and utilization, supporting a stable gross margin backdrop comparable to last quarter’s 51.59% level.

Another practical consideration this quarter is the balance between new program ramps and reorder volumes. A favorable skew toward reorder activity in Therapeutics can compress delivery timelines, supporting quarter-end revenue recognition and reducing working-capital friction. A clean delivery quarter in this cohort—on-time shipments and minimal pushouts—would not only support the guided revenue midpoint but could also preserve gross margin and help Twist Bioscience Corp hit the estimated -0.494 adjusted EPS with the implied 11.63% year-over-year improvement.

Key stock-price swing factors this quarter

The first swing factor is straightforward: revenue versus the guided 114.00–115.00 million US dollars range. Upside above the midpoint, alongside stable gross margin, should compress the adjusted loss more than linearly given cost structure dynamics, and would validate the preliminary trajectory toward the recently raised full-year revenue outlook. Conversely, any shortfall or a weaker mix that drags gross margin below the low-50% area could cap the improvement in EBIT and EPS and raise second-half execution questions.

The second swing factor is the trend in operating expenses and resulting EBIT. The current estimate of -32.15 million US dollars EBIT indicates a 7.52% year-over-year improvement, and clarity on headcount, R&D project pacing, and sales and marketing efficiency will shape whether that progress accelerates. If management highlights durable efficiency gains—without constraining customer acquisition—the market could begin to underwrite a steeper slope of loss reduction into fiscal Q4. That outcome would be supported by the adjusted EPS forecast of -0.494, which already implies a year-over-year improvement, and would likely influence sentiment for the balance of fiscal 2026.

The third swing factor relates to capital markets activity and equity overhang perception. The company filed a shelf registration that includes an at-the-market program for up to 200.00 million US dollars of common stock. While this can provide flexibility for general corporate purposes, investors are sensitive to potential dilution, and management’s commentary on capital deployment discipline will be closely watched. If revenue and margin progression reduce the perceived need to tap the ATM in the near term, that could alleviate some pressure. On the other hand, any signal of accelerated usage could weigh on post-earnings price action irrespective of operational results.

Analyst Opinions

Across recent months, the balance of published analyst views leans bullish. Among notable institutions, Canaccord Genuity initiated with a Buy rating and a 90 US dollars price target. Leerink upgraded the shares to Outperform and raised its target to 70 US dollars. In addition, the prevailing average rating across published notes trends toward Buy with a mean target in the high-80s range. While one well-followed firm reset its stance to a neutral setting even as it lifted its target to 102 US dollars, the ratio of indicated Buy or equivalent ratings remains ahead of Hold or Sell, so the majority opinion is bullish.

The bullish camp points to a few common pillars. First, the company’s top-line cadence is improving, with guidance for fiscal Q3 at roughly 114.49 million US dollars, up 19.73% year-over-year, on the heels of fiscal Q2’s 19.31% growth. This back-to-back double-digit expansion suggests that end-demand across the largest customer groups is translating into consistent bookings and shipments. Second, the gross margin profile has stabilized around the low-50% zone, evidenced by the 51.59% result last quarter, which gives analysts confidence that incremental revenue will fall through to gross profit dollars at a predictable rate. Third, management’s raised full-year revenue outlook into the 435.00–440.00 million US dollars range indicates conviction in second-half visibility, a key input for models that call for a continued narrowing of losses.

Supporting these points, bullish analysts highlight estimates showing EBIT improving to approximately -32.15 million US dollars in fiscal Q3, a 7.52% year-over-year step-up, together with an adjusted EPS forecast of -0.494, implying an 11.63% year-over-year improvement. Those metrics, if achieved, would extend a pattern of sequential improvement that began in earlier quarters and would likely reduce risk in out-year estimates. The view is that operational scale, steady mix, and measured expense growth can bridge to more significant loss reductions in fiscal Q4 and into the next fiscal year without an undue sacrifice in growth.

Another thread in positive commentary focuses on the internal composition of revenue. With Therapeutics at 40.77 million US dollars and Diagnostics at 39.96 million US dollars last quarter, the company’s largest cohorts provide the base from which guidance is set. Analysts in the bullish majority expect these groups to continue underpinning revenue, and if the company maintains delivery discipline, the quarter’s revenue should land near or above the midpoint of guidance. They also note that consistent growth in the largest cohorts can reduce variability in revenue timing and enhance predictability in gross margin, which together support valuation arguments tied to visibility.

On balance, bullish institutions are prepared to monitor the equity overhang risk associated with the shelf and at-the-market program, yet they currently see the improving revenue trajectory and loss-narrowing path as the more influential drivers of stock performance into the print. In practical terms, this means they will evaluate management’s capital allocation commentary in the context of execution against guidance. A reiteration or lift to the full-year revenue outlook, coupled with gross margin around the low-50% range and adjusted EPS close to or better than -0.494, would likely reinforce the constructive stance.

In sum, the dominant analyst narrative expects Twist Bioscience Corp to extend its track record of double-digit year-over-year revenue growth into fiscal Q3 2026, hold gross margin near recent levels, and show further progress on narrowing losses. The most affirmative views argue that favorable core-customer dynamics and controlled spending can support both near-term estimates and the trajectory toward improved profitability. As a result, the majority outlook is tilted toward positive surprise potential, with the range of outcomes most sensitive to revenue delivery versus guidance, gross margin maintenance in the low-50% band, and disciplined operating expense management.